Early safety indicators of COVID-19 convalescent plasma in 5000 patients

BACKGROUND: Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatmen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Joyner, Michael J., Wright, R. Scott, Fairweather, DeLisa, Senefeld, Jonathon W., Bruno, Katelyn A., Klassen, Stephen A., Carter, Rickey E., Klompas, Allan M., Wiggins, Chad C., Shepherd, John R.A., Rea, Robert F., Whelan, Emily R., Clayburn, Andrew J., Spiegel, Matthew R., Johnson, Patrick W., Lesser, Elizabeth R., Baker, Sarah E., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Hodge, David O., Kunze, Katie L., Buras, Matthew R., Vogt, Matthew N.P., Herasevich, Vitaly, Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Paneth, Nigel S., Verdun, Nicole C., Marks, Peter, Casadevall, Arturo
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7456238/
https://ncbi.nlm.nih.gov/pubmed/32525844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI140200
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados